SCID mice model in vivo evaluation of autologous and allogeneic dendritic cells activity on B-cell chronic lymphocytic leukemia.

Iwona Hus; Jerzy Kawiak; Grazyna Hoser; Jacek Tabarkiewicz; Sebastian Radej; Anna Dmoszynska; Jacek Rolinski

doi:10.2478/v10042-008-0101-9

Vol 47, No 4 (2009)

Original paper

Submitted: 2011-12-19

Published online: 2010-05-01

View PDF

Download PDF file

Get Citation

SCID mice model in vivo evaluation of autologous and allogeneic dendritic cells activity on B-cell chronic lymphocytic leukemia.

Iwona Hus, Jerzy Kawiak, Grazyna Hoser, Jacek Tabarkiewicz, Sebastian Radej, Anna Dmoszynska, Jacek Rolinski

DOI: 10.2478/v10042-008-0101-9

Folia Histochem Cytobiol 2009;47(4):563-570.

Vol 47, No 4 (2009)

ORIGINAL PAPERS

Submitted: 2011-12-19

Published online: 2010-05-01

Abstract

In the present study we investigated in vivo therapeutic potential of DCs vaccines in B-cell chronic lymphocytic leukemia (B-CLL). On the day 0 the SCID mice were intraperitoneally inoculated with peripheral blood mononuclear cells (PBMC) of B-CLL patients at a dose of 10-30 x 10(6) and left untreated (controls) or i.p. injected on the day 7 with 0.2 - 14.0 x 10(6) dendritic cells. DCs were generated in vitro from peripheral blood monocytes of B-CLL donors (autologous DCs) or healthy donors (allogeneic cells) and pulsed with B-CLL antigens. On the day 14, the effect of implanted cells interactions was evaluated by a counting of CD19+CD5+ human leukemic cells and human T cells in the peritoneal fluid of mice. We found, that mean numbers of CD19+CD5+ leukemic cells as well as human T cells were lowered in peritoneal fluid of mice treated with allogeneic APCs. However, we did not observe similar effects with autologous DCs.